CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-409

Chemistry Review(s)
NDA 21-409

Singulair™

Merck Research Laboratories

Prasad Peri
Division of New Drug Chemistry II
Office of New Drug Chemistry

Division of Pulmonary and Allergy Drug Products

APPEARS THIS WAY ON ORIGINAL

BEST POSSIBLE COPY
# Table of Contents

Table of Contents ........................................................................................................ 2

Chemistry Review Data Sheet ....................................................................................... 3

The Executive Summary................................................................................................. 7

I. Recommendations .................................................................................................... 7
   A. Recommendation and Conclusion on Approvability .............................................. 7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ....................................................... 7

II. Summary of Chemistry Assessments..................................................................... 7
   A. Description of the Drug Product(s) and Drug Substance(s) ............................... 7
   B. Description of How the Drug Product is Intended to be Used ......................... 9
   C. Basis for Approvability or Not-Approval Recommendation ........................... 9

III. Administrative ..................................................................................................... 9
   A. Reviewer’s Signature ......................................................................................... 9
   B. Endorsement Block ......................................................................................... 9
   C. CC Block ......................................................................................................... 9

Chemistry Assessment ................................................................................................. 10

I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2:
   S   DRUG SUBSTANCE [Name, Manufacturer] ..................................................... See CR1
   P   DRUG PRODUCT [Name, Dosage form] .......................................................... See CR1
   A   APPENDICES .................................................................................................. See CR1
   R   REGIONAL INFORMATION ......................................................................... See CR1

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1.............. See CR3
   A. Labeling & Package Insert ............................................................................. See CR3
   B. Environmental Assessment Or Claim Of Categorical Exclusion .................... See CR1

III. List Of Deficiencies To Be Communicated ......................................................... 34

REST POSSIBLE COPY
Chemistry Review Data Sheet

1. NDA 21-409

2. REVIEW #: 3

3. REVIEW DATE: 26-July, 2002

4. REVIEWER: Prasad Peri

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>28-September 2001</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

Amendment (BC) 15-July-2002
Amendment (BL) 18-July-2002
Amendment (BC) 22-July-2002
Amendment (BC) 23-July-2002
Amendment (BC) 24-July-2002
Amendment (BC) 25-July-2002
Amendment (BC) 25-July-2002
Amendment (BL) 25-July-2002

7. NAME & ADDRESS OF APPLICANT:

Name: Merck Research Laboratories (Merck & Co., Inc.)
Address: RY 33-720, P. O. Box 2000, Rahway, NJ 07065
Representative: David Altarac, MD, Director, Regulatory Affairs
Telephone: (732) 594 0135
8. DRUG PRODUCT NAME/CODE/TYPE:
   a) Proprietary Name: Singulair™
   b) Non-Proprietary Name (USAN): Montelukast Sodium
   c) Code Name/# (ONDC only):
   d) Chem. Type/Submission Priority (ONDC only):
      • Chem. Type: 3
      • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: N/A

10. PHARMACOL. CATEGORY: Leukotriene Inhibitor

11. DOSAGE FORM: Oral Granules

12. STRENGTH/POTENCY: 4 mg/

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: X Rx _____ OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    _____ SPOTS product – Form Completed
    X _____ Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:
    Cyclopropaneacetic acid, 1-(((1R)-1-(3-(1E)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, monosodium salt
CHEMISTRY REVIEW

Chemistry Review Data Sheet

C₃₅H₃₅ClINaO₃S
Molecular Weight: 608.18

17. RELATED/SUPPORTING DOCUMENTS:

A. Supporting DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>5/1/02</td>
<td>IR letter sent. See CR 1, page 42</td>
</tr>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>5/3/02</td>
<td>Page 9</td>
</tr>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>5/3/02</td>
<td>IR letter sent Page 9 See CR1</td>
</tr>
</tbody>
</table>

Action codes for DMF Table:
1 - DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 - Type 1 DMF
3 - Reviewed previously and no revision since last review
4 - Sufficient information in application
5 - Authority to reference not granted
6 - DMF not available
7 - Other (explain under "Comments")

Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
Include reference to location in most recent CMC review

B. Other Supporting Documents:

<table>
<thead>
<tr>
<th>Doc #</th>
<th>OWNER</th>
<th>ITEM REFERENCED</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>N20829</td>
<td>Merck</td>
<td>DS Info</td>
<td>Approved</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>N20830</td>
<td>Merck</td>
<td>DS Info</td>
<td>Approved</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>
18. CMC-RELATED REVIEWS:

<table>
<thead>
<tr>
<th>CONSULTS</th>
<th>SUBJECT</th>
<th>DATE FORWARDED</th>
<th>STATUS/REVIEWER</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Shelf Life Stability</td>
<td>5/02/02</td>
<td>Draft Complete</td>
<td>Dr. Guo states that the data supports the applicant's proposal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>June 17, 2002</td>
<td>of a --- shelf life.</td>
</tr>
<tr>
<td>EES</td>
<td>DS and DP Sites</td>
<td>10/23/01</td>
<td>Adequate, 4/23/02</td>
<td>All sites acceptable 4/23/02</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Proposed levels of</td>
<td>5/1/02</td>
<td>Adequate, Dr. Pei</td>
<td>No safety concerns for the levels of</td>
</tr>
<tr>
<td></td>
<td>--- in DP</td>
<td></td>
<td>OND</td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td>N/A</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Assay, identity and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>impurities method was found</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>acceptable by the FDA lab for</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NDAs 20829 and 20830. Method</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>validation for other attributes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>will be requested.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPDRA</td>
<td>Acceptability of the trade Name</td>
<td>2/21/02</td>
<td>Completed, Scott</td>
<td>Acceptable with labeling</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dallas, ODS</td>
<td>comments passed on to applicant</td>
</tr>
<tr>
<td>EA</td>
<td>Exclusion requested</td>
<td>10/23/01</td>
<td></td>
<td>Acceptable</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
</tbody>
</table>
The Chemistry Review for NDA 21-409

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

Approval from a CMC standpoint

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

The bulk drug substance is a white powder and is manufactured and packaged in

This site has been inspected and found to have an acceptable GMP status as per EES dated 4/19/02. The intermediates used in the drug substance are obtained from two chemical companies. The DMFs for the intermediates are found adequate.

All the drug substance information (regarding synthesis, manufacture and specifications) have been referenced to the approved NDA 20-829 (Singulair 4 mg and 5 mg chewable tablets).

The drug substance is

The drug product is white, granules packaged in a "aluminum foil packet with a for ease of opening. The packaged components are child resistant and senior citizen friendly.
CHEMISTRY REVIEW

Executive Summary Section

The bulk drug product is manufactured by Merck Manufacturing, West Point, PA and is packaged into individual packets at [ ] and is stability tested in Merck Manufacturing Division, Wilson, NC. All drug product manufacturing, packaging and testing facilities have an acceptable EER status.

[ ]

granules at the 10 minute time point.

Merck claims these higher levels [ ] are partly attributed to [ ] during manufacturing and partly due to more than [ ] times. Merck is investigating [ ] options to minimize the effect of [ ] on the drug product during the manufacture. Certificates of analyses for these validation batches manufactured with these controls will be provided to the Agency prior to launch of the drug product in March 2003.

With the recommendation of the Agency, the applicant has tightened the acceptance criteria for oral granules from Q=\ in 20 minutes to Q=\ in 15 minutes.

The commercial batch size is ~ packets. Stability data for lots (MR 4218- ~ packets, 1005-46- ~ packets and 1005-42- ~ packets) have been provided.

The proposed shelf life for the drug product is ~ Dr. Ted Guo (Biometrics) in his review states that the sponsor proposed ~ is supported by the stability data.

- In Chemistry Review 1 the information related to Drug substance and Drug Product was reviewed. Based on the information provided, comments were sent to the applicant in a fax dated May 7, 2002. The applicant responded to these comments in an amendment dated June 7, 2002.

- In Chemistry Review 2 the responses provided in the amendment dated June 7 were evaluated and list of deficiencies were forwarded to the applicant in a fax dated June 28, 2002. The applicant requested a teleconference with the Agency to clarify issues related to [ ] for
further submission of data by the applicant. This was held on July 10, 2002 at 10:30 AM and the applicant was informed that the dissolution specification for the drug product should be tightened. Following this teleconference, applicant was faxed CMC comments related to the proposed labeling for the packet, carton, PI and PPI.

- The applicant responded to the Agency's fax dated June 28 in an amendment dated July 15, 2002. These responses have been evaluated here, in Chemistry Review 3, along with the responses to the labeling comments provided by the agency on July 12, 2002. Several teleconferences were held between the Agency and the applicant during July 20, 2002 and July 25, 2005. Issues related to acceptance criteria for drug product were discussed. These teleconferences resulted in the applicant revising the testing to the stability protocol.

B. Description of How the Drug Product is Intended to be Used

The drug product is to be administered orally possibly with food. The approved indication is for patients 12 months to years and for patients 2 to 5 years who cannot chew tablets.

C. Basis for Approvability or Not-Approval Recommendation

All pending safety and quality issues have been resolved. Issues related to pictures on the complimentary cartons have been forwarded to the division for a divisional perspective and action.

III. Administrative

A. Reviewer's Signature

B. Endorsement Block

Chemist Name/Date: Same date as draft review

Chemistry Team Leader Name/Date

Project Manager Name/Date

C. CC Block
Redacted 32

page(s) of trade secret

and/or confidential

commercial information

(b4)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Prasad Peri
7/26/02 12:52:52 PM
CHEMIST
BC Amendments dated 24 July and 25, July 2002
and a BL amendment dated July 25 have
not been linked to this review in DFS
as they were not updated in DFS at
the time of the signoff on DFS. Document
room should close these amendments once AP action is tak

Brian Rogers
7/26/02 01:02:55 PM
CHEMIST
Signed for Guirag Poochikian

APPEARS THIS WAY
ON ORIGINAL
Chemistry Review Data Sheet

1. NDA 21-409

2. REVIEW #: 2

3. REVIEW DATE: 27-June, 2002

4. REVIEWER: Prasad Peri

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>28-September 2001</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

- Amendment 23-April-2002
- Amendment 3-May-2002
- Amendment 21-May-2002
- Amendment 7-June-2002

7. NAME & ADDRESS OF APPLICANT:

   Name: Merck Research Laboratories (Merck & Co., Inc.)
   Address: RY 33-720, P. O. Box 2000, Rahway, NJ 07065
   Representative: David Altarac, MD, Director, Regulatory Affairs
   Telephone: (732) 594 0135

8. DRUG PRODUCT NAME/CODE/TYPE:

   a) Proprietary Name: Singulair™
CHEMISTRY REVIEW
Chemistry Review Data Sheet

b) Non-Proprietary Name (USAN): Montelukast Sodium
c) Code Name/# (ONDC only):
d) Chem. Type/Submission Priority (ONDC only):
   • Chem. Type: 3
   • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: N/A

10. PHARMACOL. CATEGORY: Leukotriene Inhibitor

11. DOSAGE FORM: Granules

12. STRENGTH/POTENCY: 4 mg.

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: _X_ Rx _____OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____SPOTS product – Form Completed
   _X_ Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

   Cyclopropaneacetic acid, 1-(((1R)-1-(3-((1E)-2-(7-chloro-2-quinolinyl)ethanyl)phenyl)-3-(2-(1-
   hydroxy-1-methylethyl)phenyl)propyl(thio)methyl)-, monosodium salt

BEST POSSIBLE COPY
CHEMISTRY REVIEW

Chemistry Review Data Sheet

![Chemical structure image]

C_{35}H_{35}ClNNaO_{3}S
Molecular Weight: 608.18

17. RELATED/SUPPORTING DOCUMENTS:

A. Supporting DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>I</td>
<td>Adequate</td>
<td>5/1/02</td>
<td>IR letter sent See CR 1, page 42</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td></td>
<td>I</td>
<td>Adequate</td>
<td>5/3/02</td>
<td>Page 9</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td></td>
<td>I</td>
<td>Adequate</td>
<td>5/3/02</td>
<td>IR letter sent Page 9 See CR1</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td></td>
<td>I</td>
<td>Adequate</td>
<td>5/3/02</td>
<td>IR letter sent Page 9 See CR1</td>
</tr>
</tbody>
</table>

Action codes for DMF Table:
1 - DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 - Type I DMF
3 -Reviewed previously and no revision since last review
4 - Sufficient information in application
5 - Authority to reference not granted
6 - DMF not available
7 - Other (explain under “Comments”)

Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

Include reference to location in most recent CMC review

B. Other Supporting Documents:

<table>
<thead>
<tr>
<th>Doc #</th>
<th>OWNER</th>
<th>ITEM REFERENCED</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>N20829</td>
<td>Merck</td>
<td>DS Info</td>
<td>Approved</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>N20830</td>
<td>Merck</td>
<td>DS Info</td>
<td>Approved</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>
**18. CMC-RELATED REVIEWS:**

<table>
<thead>
<tr>
<th>CONSULTS</th>
<th>SUBJECT</th>
<th>DATE FORWARDED</th>
<th>STATUS/REVIEWER</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Shelf Life Stability</td>
<td>5/02/02</td>
<td>Draft Complete</td>
<td>Dr. Guo states that the data supports the applicant's proposal of a shelf life</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>June 17, 2002</td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>DS and DP Sites</td>
<td>10/23/01</td>
<td>Adequate, 4/23/02</td>
<td>All sites acceptable 4/23/02</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Proposed levels of</td>
<td>5/1/02</td>
<td>Adequate, Dr. Pei,</td>
<td>No safety concerns for the levels</td>
</tr>
<tr>
<td></td>
<td>in DP</td>
<td></td>
<td>OND</td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td>N/A</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Methods</td>
<td>Assay, identity and impurities method</td>
<td>2/21/02</td>
<td>Completed, Scott</td>
<td>Will be sent shortly</td>
</tr>
<tr>
<td>Validation</td>
<td>method was found acceptable by the</td>
<td></td>
<td>Dallas, ODS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FDA lab for NDAs 20829 and 20830, method validation for other attributes will be requested.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPDRA</td>
<td>Acceptability of the trade Name</td>
<td>2/21/02</td>
<td></td>
<td>Acceptable</td>
</tr>
<tr>
<td>EA</td>
<td>Exclusion requested</td>
<td>10/23/01</td>
<td></td>
<td>Acceptable</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>
The Chemistry Review for NDA 21-409

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

Approvable from a CMC standpoint

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None indicated so far

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Chemistry Review 1 found the application approvable and deficiencies were sent to the applicant in a fax dated May 7, 2002. The applicant responded to these comments in an amendments dated May 21, 2002 and June 7, 2002. They are evaluated in this review cycle.

The bulk drug substance is a white powder and is manufactured and packaged in

This site has been inspected and found to have an acceptable GMP status as per EES dated 4/19/02. The intermediates used in the drug substance are obtained from two chemical companies ——— The DMFs for the intermediates are found adequate.

All the drug substance information (regarding synthesis, manufacture and specifications) have been referenced to the approved NDA 20-829 (Singulair 4 mg and 5 mg chewable tablets).

The drug substance is

The drug product is white, ——— granules packaged in a aluminum foil packet with a ——— for ease of opening. The packaged components are child resistant and senior citizen friendly.

The bulk drug product is manufactured by Merck Manufacturing, West Point, PA and is packaged into individual packets at

and is stability tested in Merck Manufacturing Division, Wilson, NC. All drug product manufacturing, packaging and testing facilities have an acceptable EER status.

The proposed shelf life of the drug product is __________ A biometrics consult has been requested (dated 5/2/02) to evaluate the appropriateness of the proposed shelf life based on statistical analysis. Dr. Ted Guo in his draft review states that the sponsor proposed __________ is supported by the stability data.

The proposed dissolution and impurities acceptance criteria are not justified based on the data provided. They should be tightened to reflect the data. Comments are being sent to the applicant.

The commercial batch size is ______ pack(s). Stability data for lots (MR 4218-______, 1005-46-______, and 1005-42-______) have been provided.

B. Description of How the Drug Product is Intended to be Used

The drug product is to be administered orally possibly with food. The proposed indication is for patients _______ to 2 years and for patients 2 to ______ years who cannot chew tablets.

C. Basis for Approvability or Not-Approval Recommendation

The application is approvable, pending deficiencies listed at the end of the review (pages 50-51).

III. Administrative

A. Reviewer’s Signature

B. Endorsement Block

Chemist Name/Date: Same date as draft review
Chemistry Team Leader Name/Date
Project Manager Name/Date

C. CC Block
Redacted page(s) of trade secret and/or confidential commercial information (b4)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

___________________________
Prasad Peri
6/28/02 02:54:08 PM
CHEMIST

___________________________
Guiragos Poochikian
6/28/02 03:00:54 PM
CHEMIST

APPEARS THIS WAY ON ORIGINAL
NDA 21-409

Singulair™

Merck Research Laboratories

Prasad Peri
Division of New Drug Chemistry II
Office of New Drug Chemistry

Division of Pulmonary and Allergy Drug Products

BEST POSSIBLE COPY
CHEMISTRY REVIEW

Table of Contents

Table of Contents ........................................................................................................... 2
Chemistry Review Data Sheet ......................................................................................... 3
The Executive Summary ................................................................................................. 7

I. Recommendations ...................................................................................................... 7
   A. Recommendation and Conclusion on Approvability ............................................. 7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ......................................................... 7

II. Summary of Chemistry Assessments ...................................................................... 7
   A. Description of the Drug Product(s) and Drug Substance(s) .................................. 7
   B. Description of How the Drug Product is Intended to be Used ............................. 8
   C. Basis for Approvability or Not-Approval Recommendation .............................. 8

III. Administrative ........................................................................................................ 8
    A. Reviewer's Signature ......................................................................................... 8
    B. Endorsement Block ......................................................................................... 8
    C. CC Block ........................................................................................................ 8

Chemistry Assessment ................................................................................................. 9

I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2:
   S DRUG SUBSTANCE [Name, Manufacturer] ......................................................... See CR1
   P DRUG PRODUCT [Name, Dosage form] ............................................................... See CR1
   A APPENDICES .................................................................................................... See CR1
   R REGIONAL INFORMATION ............................................................................. See CR1

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 ................... See CR3
   A. Labeling & Package Insert .............................................................................. See CR3
   B. Environmental Assessment Or Claim Of Categorical Exclusion ...................... See CR1

III. List Of Deficiencies To Be Communicated ............................................................ 23

BEST POSSIBLE COPY
Chemistry Review Data Sheet

1. NDA 21-409

2. REVIEW #: 1

3. REVIEW DATE: 06-May, 2002

4. REVIEWER: Prasad Peri

5. PREVIOUS DOCUMENTS:

   Previous Documents                               Document Date
   Original                                           28-September 2001

6. SUBMISSION(S) BEING REVIEWED:

   Submission(s) Reviewed                           Document Date
   Original NDA                                       28-September-2001

7. NAME & ADDRESS OF APPLICANT:

   Name:    Merck Research Laboratories (Merck & Co., Inc.)
   Address: RY 33-720, P. O. Box 2000, Rahway, NJ 07065
   Representative: David Altarac, MD, Director, Regulatory Affairs
   Telephone: (732) 594 0135

8. DRUG PRODUCT NAME/CODE/TYPE:

   a) Proprietary Name: Singulair™
   b) Non-Proprietary Name (USAN): Montelukast Sodium
CHEMISTRY REVIEW

Chemistry Review Data Sheet

c) Code Name/# (ONDC only):
d) Chem. Type/Submission Priority (ONDC only):
   • Chem. Type: 3
   • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: N/A

10. PHARMACOL. CATEGORY: Leukotriene Inhibitor

11. DOSAGE FORM: Granules

12. STRENGTH/POTENCY: 4 mg

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: _X_ Rx     ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    ______SPOTS product – Form Completed
    ___X___Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Cyclopropaneacetic acid, 1-(((1R)-1-(3-((1E)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, monosodium salt

BEST POSSIBLE COPY
CHEMISTRY REVIEW
Chemistry Review Data Sheet

C_{35}H_{35}CINaO_{3}S
Molecular Weight: 608.18

17. RELATED/SUPPORTING DOCUMENTS:

A. Supporting DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>5/1/02</td>
<td>IR letter sent. See CR 1, page 42</td>
</tr>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>5/3/02</td>
<td>Page 9</td>
</tr>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>5/3/02</td>
<td>IR letter sent Page 9 See CR1</td>
</tr>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>5/3/02</td>
<td>IR letter sent Page 9 See CR1</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 - DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 - Type 1 DMF
3 - Reviewed previously and no revision since last review
4 - Sufficient information in application
5 - Authority to reference not granted
6 - DMF not available
7 - Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

3 Include reference to location in most recent CMC review

B. Other Supporting Documents:

<table>
<thead>
<tr>
<th>Doc #</th>
<th>OWNER</th>
<th>ITEM REFERENCED</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>N20829</td>
<td>Merck</td>
<td>DS Info</td>
<td>Approved</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>N20830</td>
<td>Merck</td>
<td>DS Info</td>
<td>Approved</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>
18. CMC-RELATED REVIEWS:

<table>
<thead>
<tr>
<th>CONSULTS</th>
<th>SUBJECT</th>
<th>DATE FORWARDED</th>
<th>STATUS/REVIEWER</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Shelf Life Stability</td>
<td>5/02/02</td>
<td>Pending with Dr. Gebert</td>
<td>Dr. Gebert was sent a consult on 5/2/02</td>
</tr>
<tr>
<td>EES</td>
<td>DS and DP Sites</td>
<td>10/23/01</td>
<td>Adequate, 4/23/02</td>
<td>All sites acceptable 4/23/02</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Proposed levels of _____ in DP</td>
<td>5/1/02</td>
<td>Adequate, Dr. Pei, OND</td>
<td>No safety concerns for the levels of ________</td>
</tr>
<tr>
<td>Biopharm</td>
<td>N/A</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Methods Validation</td>
<td>To be sent</td>
<td></td>
<td></td>
<td>Will be sent shortly</td>
</tr>
<tr>
<td>OPDRA</td>
<td>Acceptability of the trade Name</td>
<td>2/21/02</td>
<td>Completed, Scott Dallas, ODS</td>
<td>Acceptable</td>
</tr>
<tr>
<td>EA</td>
<td>Exclusion requested</td>
<td>10/23/01</td>
<td></td>
<td>Acceptable</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
</tbody>
</table>
The Chemistry Review for NDA 21-409

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

Approvable from a CMC standpoint

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None indicated so far

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

The bulk drug substance is a white powder and is manufactured and packaged in

This site has been inspected and found to have an acceptable GMP status as per EES dated 4/19/02. The intermediates used in the drug substance are obtained from two chemical companies. The DMFs for the intermediates are found adequate.

All the drug substance information (regarding synthesis, manufacture and specifications) have been referenced to the approved NDA 20-829 (Singulair 4 mg and 5 mg chewable tablets).

The drug substance is:

The drug product is white, granules packaged in a aluminum foil packet with a for ease of opening. The packaged components are child resistant and senior citizen friendly.

The bulk drug product is manufactured by Merck Manufacturing, West Point, PA and is packaged into individual packets at and is stability tested in Merck Manufacturing Division, Wilson, NC. All drug product manufacturing, packaging and testing facilities have an acceptable EER status.

There are some serious issues with the stability of the drug product when mixed with baby foods like rice, applesauce, etc.
The proposed shelf life of the drug product is _____ A biometrics consult has been requested (dated 5/2/02) to evaluate the appropriateness of the proposed shelf life based on statistical analysis.

The proposed dissolution and impurities acceptance criteria are not justified based on the data provided. They should be tightened to reflect the data.

The commercial batch size is _______ packets. Stability data for lots (MR 4218-____packets, 1005-46-____packets and 1005-42-____packets) have been provided.

B. Description of How the Drug Product is Intended to be Used

The drug product is to be administered orally possibly with food. The proposed indication is for patients _______ to 2 years and for patients 2 to _____ years who cannot chew tablets.

C. Basis for Approvability or Not-Approval Recommendation

The application is approvable, pending deficiencies listed at the end of the review (pages 50-51).

III. Administrative

A. Reviewer’s Signature

B. Endorsement Block

ChemistName/Date: Same date as draft review
ChemistryTeamLeaderName/Date
ProjectManagerName/Date

C. CC Block
Redacted 45 page(s) of trade secret and/or confidential commercial information (b4)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Prasad Peri
5/6/02 04:19:35 PM
CHEMIST

Guiragos Poochikian
5/6/02 04:41:44 PM
CHEMIST

APPEARS THIS WAY
ON ORIGINAL